0001140361-19-020255.txt : 20191112 0001140361-19-020255.hdr.sgml : 20191112 20191112080038 ACCESSION NUMBER: 0001140361-19-020255 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20191112 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191112 DATE AS OF CHANGE: 20191112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 191206208 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 form8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 12, 2019

BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)


Delaware
(State or Other Jurisdiction of Incorporation)
001-01136
(Commission File Number)
22-0790350
(IRS Employer Identification Number)
 
 
 
 
430 East 29th Street, 14th Floor
New York, NY, 10016
(Address of Principal Executive Office)
 

Registrant’s telephone number, including area code: (212) 546-4000

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
 BMY
New York Stock Exchange
1.000% Notes due 2025
 BMY 25
New York Stock Exchange
1.750% Notes due 2035
 BMY 35
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 8.01
Other Events.

On November 12, 2019, Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) issued a press release announcing that it has extended the expiration date of its previously announced (i) offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes issued by Bristol-Myers Squibb and cash and (ii) related solicitations of consents (each, a “Consent Solicitation” and, collectively, the “Consent Solicitations”) to adopt certain amendments (the “Amendments”) that would eliminate substantially all restrictive covenants and certain events of default and other provisions in each of the indentures governing the Celgene Notes. Bristol-Myers Squibb extended such expiration date from 5:00 p.m., New York City time, on November 13, 2019, to 5:00 p.m., New York City time, on November 15, 2019 (as the same may be further extended, the “Expiration Date”).

The Exchange Offers and Consent Solicitations were commenced in connection with Bristol-Myers Squibb’s planned acquisition of Celgene (the “Merger”) and are being made solely pursuant to the terms and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement dated April 17, 2019 and the related letter of transmittal, each as amended by the press releases dated May 1, 2019, May 24, 2019, June 28, 2019, September 23, 2019, October 8, 2019, October 18, 2019, October 30, 2019, November 1, 2019, November 5, 2019, November 7, 2019 and the attached press release, in a private offering exempt from, or not subject to, registration under the Securities Act of 1933, as amended. The Exchange Offers and Consent Solicitations are conditioned upon the closing of the Merger, which condition may not be waived by Bristol-Myers Squibb, and certain other conditions that may be waived by Bristol-Myers Squibb.

The settlement date of the Exchange Offers and Consent Solicitations is expected to occur promptly after the Expiration Date and on or about the closing date of the Merger. The closing of the Merger is expected to occur by the end of 2019 and, as a result, the Expiration Date may be further extended one or more times. Bristol-Myers Squibb will provide notice of any such extension in advance of the Expiration Date.

Supplemental indentures effecting the Amendments relating to the Celgene Notes were executed on May 1, 2019. Such supplemental indentures will only become operative upon the settlement date of the Exchange Offers.

A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein in its entirety.

Item 9.01
Financial Statements and Exhibits.

 
(d)
Exhibits
 
The following exhibits are included as part of this Current Report on Form 8-K:

Exhibit
No.
   Description
     
99.1
  
Press Release of Bristol-Myers Squibb Company, dated November 12, 2019.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit
No.
   Description
     
 
Press Release of Bristol-Myers Squibb Company, dated November 12, 2019.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BRISTOL-MYERS SQUIBB COMPANY
     
Dated: November 12, 2019
By:
/s/ Katherine R. Kelly
  
 
Name:
Katherine R. Kelly
 
Title:
Corporate Secretary

 
 EX-99.1 2 ex99_1.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY
Exhibit 99.1

Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
 
NEW YORK, November 12, 2019 – Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bristol-Myers Squibb Notes”) and cash and the related consent solicitations (the “Consent Solicitations”) being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments (the “Amendments”) to the indentures governing the Celgene Notes. Bristol-Myers Squibb hereby extends such expiration date from 5:00 p.m., New York City time, on November 13, 2019, to 5:00 p.m., New York City time, on November 15, 2019 (as the same may be further extended, the “Expiration Date”).
 
On the early participation date of May 1, 2019, requisite consents were received and supplemental indentures were executed, eliminating substantially all restrictive covenants and certain events of default and other provisions in each of the indentures governing the Celgene Notes. Such supplemental indentures will only become operative upon the settlement date of the Exchange Offers.
 
The Exchange Offers and Consent Solicitations are being made pursuant to the terms and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement dated April 17, 2019 and the related letter of transmittal hereby, each as amended by the press releases dated May 1, 2019, May 24, 2019, June 28, 2019, September 23, 2019, October 8, 2019, October 18, 2019, October 30, 2019, November 1, 2019, November 5, 2019, November 7, 2019 and as amended hereby, and are conditioned upon the closing of Bristol-Myers Squibb’s acquisition of Celgene (the “Merger”), which condition may not be waived by Bristol-Myers Squibb, and certain other conditions that may be waived by Bristol-Myers Squibb.
 
The settlement date for the Exchange Offers is expected to occur promptly after the Expiration Date and on or about the closing date of the Merger. The closing of the Merger is expected to occur by the end of 2019. As a result, the Expiration Date may be further extended one or more times. Bristol-Myers Squibb will provide notice of any such extension in advance of the Expiration Date.
 
Except as described in this press release, all other terms of the Exchange Offers and Consent Solicitations remain unchanged.
 
As of 5:00 p.m., New York City time, on November 11, 2019, the principal amounts of Celgene Notes set forth in the table below had been validly tendered and not validly withdrawn:
 
1
Title of Series
CUSIP Number
   
Aggregate
Principal
Amount
Outstanding
      
Celgene Notes Tendered as of
5:00 p.m., New York City
time, on November 11, 2019
   
Principal
Amount
    
Percentage
2.875% Senior Notes due 2020
151020AQ7
  
$
1,500,000,000
    
$
1,051,332,000
      
70.09
%
3.950% Senior Notes due 2020
151020AE4
  
$
500,000,000
    
$
435,801,000
      
87.16
%
2.875% Senior Notes due 2021
151020BC7
  
$
500,000,000
    
$
430,752,000
      
86.15
%
2.250% Senior Notes due 2021
151020AV6
  
$
500,000,000
    
$
448,595,000
      
89.72
%
3.250% Senior Notes due 2022
151020AH7
  
$
1,000,000,000
    
$
827,132,000
      
82.71
%
3.550% Senior Notes due 2022
151020AR5
  
$
1,000,000,000
    
$
879,220,000
      
87.92
%
2.750% Senior Notes due 2023
151020AX2
  
$
750,000,000
    
$
621,730,000
      
82.90
%
3.250% Senior Notes due 2023
151020BA1
  
$
1,000,000,000
    
$
907,054,000
      
90.71
%
4.000% Senior Notes due 2023
151020AJ3
  
$
700,000,000
    
$
628,752,000
      
89.82
%
3.625% Senior Notes due 2024
151020AP9
  
$
1,000,000,000
    
$
872,125,000
      
87.21
%
3.875% Senior Notes due 2025
151020AS3
  
$
2,500,000,000
    
$
2,364,569,000
      
94.58
%
3.450% Senior Notes due 2027
151020AY0
  
$
1,000,000,000
    
$
944,705,000
      
94.47
%
3.900% Senior Notes due 2028
151020BB9
  
$
1,500,000,000
    
$
1,408,946,000
      
93.93
%
5.700% Senior Notes due 2040
151020AF1
  
$
250,000,000
    
$
244,732,000
      
97.89
%
5.250% Senior Notes due 2043
151020AL8
  
$
400,000,000
    
$
390,718,000
      
97.68
%
4.625% Senior Notes due 2044
151020AM6
  
$
1,000,000,000
    
$
922,572,000
      
92.26
%
5.000% Senior Notes due 2045
151020AU8
  
$
2,000,000,000
    
$
1,891,762,000
      
94.59
%
4.350% Senior Notes due 2047
151020AW4
  
$
1,250,000,000
    
$
1,141,150,000
      
91.29
%
4.550% Senior Notes due 2048
151020AZ7
  
$
1,500,000,000
    
$
1,343,744,000
      
89.58
%
 
Documents relating to the Exchange Offers and Consent Solicitations will only be distributed to eligible holders of Celgene Notes who complete and return an eligibility form confirming that they are either a “qualified institutional buyer” under Rule 144A or not a “U.S. person” and outside the United States under Regulation S for purposes of applicable securities laws. Except as amended by the press releases dated May 1, 2019, May 24, 2019, June 28, 2019, September 23, 2019, October 8, 2019, October 18, 2019, October 30, 2019, November 1, 2019, November 5, 2019, November 7, 2019 and as amended hereby, the complete terms and conditions of the Exchange Offers and Consent Solicitations are described in the confidential offering memorandum and consent solicitation statement dated April 17, 2019 and the related letter of transmittal, copies of which may be obtained by contacting Global Bondholder Services Corporation, the exchange agent and information agent in connection with the Exchange Offers and Consent Solicitations, at (866) 470 3900 (U.S. toll-free) or (212) 430 3774 (banks and brokers). The eligibility form is available electronically at: https://gbsc-usa.com/eligibility/bristol-myers.
 
This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful. The Exchange Offers and Consent Solicitations are being made solely pursuant to the confidential offering memorandum and consent solicitation statement dated April 17, 2019, as amended by the press releases dated May 1, 2019, May 24, 2019, June 28, 2019, September 23, 2019, October 8, 2019, October 18, 2019, October 30, 2019, November 1, 2019, November 5, 2019, November 7, 2019 and as amended hereby, and the related letter of transmittal and only to such persons and in such jurisdictions as are permitted under applicable law.

2
The Bristol-Myers Squibb Notes offered in the Exchange Offers have not been registered under the Securities Act of 1933, as amended, or any state securities laws. Therefore, the Bristol-Myers Squibb Notes may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any applicable state securities laws.

Cautionary Statement Regarding Forward-Looking Statements
 
This press release contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the research, development and commercialization of pharmaceutical products and Bristol-Myers Squibb’s pending acquisition of Celgene (the “Merger”). These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on historical performance and current expectations and projections about Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond Bristol-Myers Squibb’s and Celgene’s control and could cause Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to, the completion of the Merger may not occur on the anticipated terms and timing or at all; a condition to the closing of the Merger may not be satisfied; the completion of the OTEZLA divestiture by Celgene does not occur on the anticipated timing; the combined company will have substantial indebtedness following the completion of the Merger; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the Merger; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company decline following the Merger; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the Merger has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb’s and Celgene’s operating results. No forward-looking statement can be guaranteed.
 
3
Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s and Celgene’s respective business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s and Celgene’s respective Annual Reports on Form 10-K for the year ended December 31, 2018, as updated by their subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this press release are made only as of the date of this document and except as otherwise required by applicable law, neither Bristol-Myers Squibb nor Celgene undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
 
Contacts

Media:
609-252-3345
media@bms.com

Investors:
Tim Power
609-252-7509
timothy.power@bms.com


4
 EX-101.SCH 3 bmy-20191112.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bmy-20191112_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bmy-20191112_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Listings [Table] Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Listings [Line Items] Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] 1.750% Notes due 2035 [Member] 1.000% Notes due 2025 [Member] EX-101.PRE 6 bmy-20191112_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image00001.jpg begin 644 image00001.jpg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end XML 8 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 4 97 1 false 3 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports form8k.htm bmy-20191112.xsd bmy-20191112_def.xml bmy-20191112_lab.xml bmy-20191112_pre.xml ex99_1.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bmy-20191112_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "bmy-20191112_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bmy-20191112_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bmy-20191112.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 37, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 2, "memberStandard": 1, "nsprefix": "bmy", "nsuri": "http://bms.com/20191112", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20191112to20191112", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://bms.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20191112to20191112", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "bmy_One000NotesDue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "localname": "One000NotesDue2025Member", "nsuri": "http://bms.com/20191112", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One750NotesDue2035Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "localname": "One750NotesDue2035Member", "nsuri": "http://bms.com/20191112", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document and Entity Information
Nov. 12, 2019
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 12, 2019
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code DE
Entity File Number 001-01136
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One 430 East 29th Street
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 212
Local Phone Number 546-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000014272
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY 25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY 35
Security Exchange Name NYSE
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 form8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2019-11-12 2019-11-12 0000014272 bmy:One000NotesDue2025Member 2019-11-12 2019-11-12 0000014272 bmy:One750NotesDue2035Member 2019-11-12 2019-11-12 0000014272 us-gaap:CommonStockMember 2019-11-12 2019-11-12 false 0000014272 8-K 2019-11-12 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 430 East 29th Street 14th Floor New York NY 10016 212 546-4000 false false false false Common Stock, $0.10 Par Value BMY NYSE 1.000% Notes due 2025 BMY 25 NYSE 1.750% Notes due 2035 BMY 35 NYSE false ZIP 15 0001140361-19-020255-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-19-020255-xbrl.zip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end